Novartis Investigative Site

Kure, Hiroshima 737-0023

0 studies enrolling now · 7 studies all time

What they study most

Acute Heart Failure, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Diffuse Large B-cell Lymphoma, Multiple Myeloma

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed